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substitutions/site/month). Following seroconversion, there was
a striking increase in viral diversity. Most seroconverters had
viral variants that showed evidence of positive selection, which
was seen mainly postseroconversion. Conclusions: The high viral
diversity before a reduction in HBV DNA and before HBeAg sero-
conversion, could either be related to occurrence of stochastic
mutations that lead to a break in immune tolerance, or increased
immune reactivity that drives escape mutations. In a follow-up
study, we examined the long term evolution of HBV quasispecies
and whether the increase in viral diversity could be conﬁrmed.
Furthermore, we sought to determine if this increase in viral
diversity could result in creation of new CpG motifs, which could
stimulate Toll Receptor 9. TLR9 is one member of a family of
highly conserved molecular pattern recognition receptors-toll
like receptors, and is stimulated by unmethylated CpG dinu-
cleotides resulting in activation of the innate immune response
and consequently adaptive immune response. In this study, we
analyzed if there were any CpG sites in the HBV genome of
chronic hepatitis B patients and their relationship with HBeAg
seroconversion, using Eight HBeAg seroconverters followed up
6–10 years before seroconversion were included. Serum samples
of 5 to 9 time points before HBeAg seroconversion were used
in the study. Seven non-seroconverters with matching follow up
period and stored serum samples were involved as controls. An
identical methodology was used to evaluate 20 clones per serum
sample and analysed using the same methodology as previously.
HBV CpGs status was analyzed with the sequence alignments.
Results: The HBV quasispecies viral diversity gradually increased
from 1.4×10-3 to 1.2×10-2 within 9 years before HBeAg serocon-
version. Positive selection was detected in 5 of 8 seroconverters
in the study period. New CpG motifs also emerged before HBeAg
seroconversion. The increase of viral diversity was closely corre-
lated with the reduction of HBV DNA, HBeAg levels and increase
in frequency of precore stop codon mutation.
Conclusion: The gradual increase of HBV quasispecies over time
before HBeAg seroconversion could be related to accumulation
of stochastic mutations which result in occurrence of new CpG
motifs that activated the innate immune response and break the
immune tolerance leading to HBeAg seroconversion.
CS1-03 Immunological Effects of Type I Interferons in
Hepatitis B Revisited: How Does Interferon Work
against HBV?
Heiner Wedemeyer*. Klinik für Gastroenterologie, Hepatologie
und Endkrinologie, Medizinische Hochschule Hannover,
Hannover, Germany
Type I interferons have been used for almost 25 years to treat
hepatitis virus infections. While HCV infection can be cured in
50-80% of cases with IFN-based treatment regimens, the goal
of IFN-therapy of HBV infection is to induce an immune control
which is either associated with HBe seroconversion or even loss
of HBsAg. Obvious advantages of IFN therapies of chronic hep-
atitis B are ﬁnite treatment durations, the lack of resistance
development and higher off-treatment sustained response rates
as compared to HBV polymerase inhibitors. However, IFN alfa
may induce various side effects and the direct antiviral potency
is much weaker as compared to the recently approved nucleoside
and nucleotide analogues. The detailed mode of action of IFN
alfa in the treatment of chronic hepatitis B is poorly deﬁned.
Different effect of IFNa have been proposed: (i) IFNa directly
inhibits HBV replication which has been conﬁrmed by in vtro
models of HBV replication. (ii) IFNa may display various effects
on cells of the adaptive immune system including dendritic cells
and T cells. Some but not all studies suggest an impairment of
dendritic cells in chronic hepatitis B and IFNa may may enhance
antigen presentation, cytokine production and maturation of
dendritic cells. If IFNa treatment is associated with a reduction
of the in HBV infection increased frequency of regulatory T
cells (Tregs) has not been studied in detail yet. Impaired CD8+
T cell function is associated with a higher expression of PD-1
expression and blocking PD1-signalling can restore T cell activity.
It is generally believed that T cell function should be increased
by IFNa, however, IFNa has also antiproliferative capacities and
may therefore impair T cell proliferation. (iii) IFNa is believed
to enhance NK cell functions. We gained evidence that IFNa
increases the cytotoxic activity of NK cells via various mecha-
nisms including upregulation of certain molecules such as TRAIL.
(iv) The potential effects of IFNa on humoral immunity against
HBV are poorly deﬁned but several studies have shown already
that B cell priming and BCR crosslinking is improvied by IFNa.
(v) Toll-like receptor-2 expression is reduced in HBeAg-positive
hepatitis B. Preliminary data suggest that IFNa may increase
TLR-2 expression.
Overall, IFNa treatment is associated with a reduced virion
productivity. To what extent this due to direct intracellular
mechanisms or deletion of HBV-infected cells remains to be
determined. Future studies will have to deﬁne in more de-
tail which patients are good candidates of IFNa treatment and
which patients may beneﬁt from combination therapies with HBV
polymerase inhibitors.
CS1-04 Gender and HBV – Interaction between Human
Sex Hormones and HBV Transcription/Replication
Pei-Jer Chen*. National Taiwan University and Hospital, Taipei,
Taiwan
One interesting outcome of chronic hepatitis B virus infection
has been a more common development of end-stage liver dis-
eases in males than females. This gender disparity is more
striking in HBV-related liver cancer, in which male patients usu-
ally outnumber females to 5-7 folds. The hypothesis is proposed
either males more vulnerable to HBV-carcinogenesis or females
more protective against this process, or both. The hypothesis
has been supported by epidemiological investigations in which
higher androgen levels are correlated with more risk of HCC in
male carriers, and use of estrogen supplements reduces HCC
in female carriers. Now we present the results how human sex
hormones axis interacts with HBV. It was found that androgen
receptor could bind directly to HBV genome, via enhancer I, to
augment HBV transcription and replication. Besides, androgen
receptor can cooperate with HBV X protein to enhance down-
stream cancer-promoting pathway. In contrast, there are data
indicating female estrogen receptor able to down regulate HBV
gene transcription, maybe via a remodeling of viral genome. The
addition of estrogen to male HBV transgenic mice could reduce
HBV titers. These results may explain the mechanisms for a male
susceptibility to HBV-related end stage liver diseases and might
point out directions to anti-viral targets.
CS1-05 Immune Evasion and the Liver
Xuefan Bai *. Department of Infectious Diseases, Tangdu
Hospital, Fourth Military Medical University, Xi’an, China
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CS2-01 Clostridium difﬁcile Infections
Po-Ren Hsueh*. Divisions of Clinical Microbiology and Infectious
Diseases, Departments of Laboratory, Medicine and Internal
Medicine, National Taiwan University Hospital, National Taiwan;
University College of Medicine, Taipei, Taiwan
Currently, Clostridium difﬁcile rivals methicillin-resistant
Concurrent Sessions S5
Staphylococcus aureus (MRSA) as the most common organism
to cause healthcare-associated infections in the United States.
Incidence of C. difﬁcile infection (CDI) has also increased in
Canada, Europe, and other parts of the world. CDI is associated
with increased lengths of hospital stay, medical costs, morbidity,
and mortality (attributable mortality rate of 6.9% at 30 days
after diagnosis and 16.7% at 1 year) among hospitalized patients.
Nearly every antibiotic along with gastric acid suppression has
been associated with CDI. Among these, cephalosporins, ampi-
cillin, and clindamycin remain important predisposing agents.
Fluoroquinolones, previously infrequently associated with CDI,
have been found to be one of the primary predisposing an-
timicrobials in recent studies. A positive result of a test for
toxigenic C. difﬁcile and/or its toxins in a patient with diarrhea
is considered to be diagnostic for CDI. Most reports of increases
in the incidence and severity of CDI have been associated with
the BI/NAP1/027 strain of C. difﬁcile. This strain produces more
toxins A and B in vitro than do many other strains of C. difﬁcile,
produces binary toxin, and is highly resistant to ﬂuoroquinolones.
Metronidazole and vancomycin remain the primary options for
the treatment of CDI. Several studies suggest that rates of re-
sponse to treatment of CDI with metronidazole are declining and
statistically superior rates of response to vancomycin treatment
for severe disease with metronidazole treatment. Two antimicro-
bials (nitazoxanide and rifaximin) available in the United States
have been used successfully for CDI treatment but lack United
States Food and Drug Administration approval for this indication.
Experimental treatments currently in clinical development in-
clude a toxin-binding polymer (tolevamer), two poorly absorbed
antimicrobials (OPT-80 [diﬁmicin] and ramoplanin), monoclonal
antibodies, and a C. difﬁcile vaccine. General strategies to
prevent and reduce the risk of CDI include adherence of antimi-
crobial usage restriction and stewardship guidelines, preventing
the patient from being exposed to C. difﬁcile (disinfection and
barrier precautions), and meticulous hand hygiene, and probable
implement of probiotics.
CS2-02 Streptococcus suis Infections in Humans
Constance Schultsz*. Oxford University Clinical Research
Unit/Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
and Center for Poverty-related Communicable Diseases,
Academic Medical Centre, Amsterdam, the Netherlands
Streptococcus suis is a Gram-positive coccus, causing menin-
gitis, septicaemia, pneumonia, and purulent arthritisis in pigs.
Human infection is acquired through exposure to colonized pigs
or contaminated pig meat. Infection is likely to occur through
direct contact, e.g. through skin lesions during butchering, but
other routes of infection, such as gastro-intestinal, cannot be
excluded. In the past few years the number of reported S. suis
infections in humans has increased signiﬁcantly, with most cases
originating in Southeast Asia where there exists a high density
of pig farming. Increased awareness, improved diagnostics and
the occurrence of outbreaks have contributed to this increase.
Meningitis and sepsis are the most common clinical manifestation
of human S. suis infection. In Vietnam, S. suis is the most com-
mon cause of acute bacterial meningitis in adults. Infections in
children are extremely rare. Meningitis is frequently complicated
by sensineural hearing loss. Adjuvant treatment with dexam-
ethasone is associated with protection against the hearing loss
in S. suis meningitis. S. suis is sensitive to penicillin, although in
very rare cases penicillin resistance has been reported, but high
rates of resistance to tetracycline and erythromycine have been
reported from human and pig isolates worldwide.
Human infections are almost always caused by S. suis serotype 2
(determined by the capsule polysaccharide), whilst infection in
pigs is caused by a number of the 35 known serotypes. Molecular
typing suggests that a very limited number of clones is respon-
sible for human infection. Whole genome sequencing of S. suis
serotype 2 strains indicates that strains of the same clonal com-
plex are highly related and that variation predominantly occurs
through horizontal transfer of mobile genetic elements.
Increased awareness from both clinicians and microbiologists is
needed to fully appreciate the importance of S. suis as a human
pathogen.
CS2-03 Streptococcus pyogenes Emm Type,
Superantigens and Macrolid Resistance
Xuzhuang Shen*. Education Department, Beijing Children’s
Hospital Afﬁliated to Capital Medical University, Beijing, China
Group A streptococci (GAS) are one of the most common human
pathogens that cause both invasive and noninvasive infections.
GAS associated diseases are more common in children than adults
and clinical presentation ranges from pharyngitis and impetigo
to invasive infections particularly acute rheumatic fever and
acute glomerulonephritis. The M protein is an important viru-
lence determinant in GAS which is determined by the emm gene.
Currently, more than 170 emm types and 750 emm subtypes of
group A streptococci have been described. Studies of GAS emm
typing distribution performed worldwide, have shown a differing
distribution of emm types in different countries and regions SAgs
are thought to contribute to the pathogenesis of severe GAS
infections by virtue of their potent immunostimulatory activ-
ity and the distribution of proﬁles of genes encoding SAgs has
been used as an additional epidemiological tool to explore the
genomic heterogeneity and possible correlation between toxin
gene content and disease type. Since the late 1990s, resistance
to macrolides has been increasingly detected in S. pyogenes in
several European countries and other parts of the world such as
Korea. There are two primary phenotypes of macrolide resistance
in S. pyogenes: the M phenotype mediated by the mef genes and
the MLSB phenotype mediated by the ermB genes. The latter
phenotype can be constitutive, generally mediated by the ermB
gene, or inducible, generally mediated by the ermA subclass TR
(ermA) gene. Many studies have presented evidence that the
phenotypes and R genes of S. pyogenes have changed over time.
We analyzed the emm type and detected the susceptibilities of
antibiotics to these strains and their phenotype of macrolide
resistance. We also investigated the virulence factors including
the superantigens of the strains. Here, we will report that there
were high resistance rates against macrolides in GAS isolates
collected from Chinese pharyngitis and scarlet fever patients
and that the R-gene was mainly the ermB gene. We also found
that the pattern of the emm-type distribution of GAS strains
from Chinese pediatric patients changed with time and there is a
change in the antimicrobial susceptibility and distribution of the
R-gene in a large collection of S. pyogenes clinical isolates from
pediatric patients during the periods 1993 to 1994 and 2005 to
2008, and to establish its association with the emm-type shift.
CS2-04 VanA Type Vancomycin Resistant Enterococci in
China
Bo Zheng. Institute of Clinical Pharmacology, Peking University
First Hospital, Beijing, China
Most of the vanA type VRE in China were E. faecium. The re-
sistance rates of the vanA type vancomycin reisitant entericocci
isolates to erythromycin, levoﬂoxacin, ampicillin and rifampin
were 96.7%, 91.7%, 88.3% and 80.8%. All VRE isolates were
susceptible to linezolid. Multilocus sequence typing (MLST) iden-
tiﬁed most of the VRE isolates belonged to clonal complexes
CC17. Vancomycin resistance of vanA type E. faecium isolates
was transferred at a frequency of 7.0 ×10-1 to 2.3×10-7 between
E. faecium strains during ﬁlter mating. Two of the plasmids,
pZB18 (67 kbp) and pZB22 (200 kbp), were highly conjugative
and were able to transfer at high frequencies of around 10-4 and
